NCT05445908已完成2 期
A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 184
- 试验地点
- 2
- 主要终点
- Incidence and severity of adverse events (AEs)
研究概览
简要总结
The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced, recurrent or metastatic TNBC and HR+/HER2- BC .The study is divided into three parts.Part 1（TNBC）: exploratory phase of the efficacy and safety of the combination treatment. Part 2（TNBC）: The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 . Part 3（HR+/HER2- BC）: The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females aged ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF);
- •Histological and/or cytological diagnosis of TNBC or HR+/HER2- BC based on pathology reports on recent biopsy samples or other pathological samples (central laboratory confirmation is not required)；
- •Patients have not received prior systemic chemotherapy for locally advanced, recurrent and metastatic disease；
- •Ability to provide fresh or archival tumor tissue for biomarker testing and analysis;
- •Patients with at least one measurable lesion per RECIST v1.1 criteria, and patients with only skin or bone lesions cannot be enrolled;
- •Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with an expected survival of ≥ 12 weeks;
- •Adequate organ and bone marrow function;
- •Patients must recover from all toxicities due to prior treatment (recovery to ≤ Grade 1 based on CTCAE v5.0 assessment, or meeting the inclusion criteria in the protocol) with the exception of alopecia and vitiligo;
- •Female subjects of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception during the study treatment period and for 6 months after the end of dosing (see Appendix for specific contraceptive measures);
- •Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.
排除标准
- •History of other malignancies;
- •Patients with a history of central nervous system (CNS) metastases or current CNS metastases.
- •Imaging (CT or MRI) shows that the tumor has invaded large blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study；
- •Received any systemic immune-stimulatory agents within 4 weeks prior to the first dose of study; Received any traditional Chinese medicine for approved anti-tumor indications within 2 weeks prior to the first dose of study;
- •Received other clinical investigational drugs within 4 weeks or major surgery within 4 weeks prior to the first dose of the study treatment;
- •Patients who required systemic corticosteroids (> 10 mg/day prednisone or equivalent; low-dose corticosteroids are allowed, such as ≤10 mg/day prednisone or equivalent, if the dose is stable for 4 weeks), or other immunosuppressive therapy within 2 weeks prior to the first dose. Steroids are allowed as prophylaxis for hypersensitivity reactions;
- •Patients who occurred arteriovenous thrombosis within 6 months prior to the first dose of study treatment，Such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism, etc.
- •Prior treatment with a TROP2-targeted drug or checkpoint inhibitor ;
- •Serious or uncontrolled cardiac disease or clinical symptoms requiring treatment；
- •Patients with (noninfectious) interstitial lung disease (ILD) or history of pneumonia requiring steroid therapy; patients with serious pulmonary function impairment due to lung disease;
- •Uncontrolled systemic disease as judged by the investigator, included uncontrolled hypertension, uncontrolled diabetes, pesence of pleural effusion, pericardial effusion, or ascites that is clinically symptomatic or requires repeated drainage;
- •Active autoimmune disease requiring systemic treatment within the past 2 years;
- •Active hepatitis B or hepatitis C; known history of positive human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS); positive syphilis antibody test;
- •Known hypersensitivity to the study drug or any of its components, or severe allergic reactions to other monoclonal antibodies;
- •Pregnant or lactating women;
- •Any patient whose condition deteriorates rapidly during the screening process prior to the first dose, such as severe changes in performance status, unstable pain requiring adjustment of analgesic therapy, etc;
- •Other circumstances that, in the opinion of the investigator, are not appropriate for participation in this study.
研究组 & 干预措施
SKB264+KL-A167（Part1，TNBC）
Experimental
Participants received SKB264 followed by KL-A167
干预措施: KL-A167 (Drug)
SKB264+KL-A167（Part1，TNBC）
Experimental
Participants received SKB264 followed by KL-A167
干预措施: SKB264 (Drug)
SKB264+KL-A167（Part3，HR+/HER2- BC）
Experimental
Participants received SKB264 followed by KL-A167
干预措施: SKB264 (Drug)
SKB264+KL-A167（Part3，HR+/HER2- BC）
Experimental
Participants received SKB264 followed by KL-A167
干预措施: KL-A167 (Drug)
SKB264+KL-A167（Part2，TNBC）
Experimental
Participants received SKB264 followed by KL-A167
干预措施: SKB264 (Drug)
SKB264（Part2，TNBC）
Experimental
Participants received SKB264
干预措施: SKB264 (Drug)
SKB264+KL-A167（Part2，TNBC）
Experimental
Participants received SKB264 followed by KL-A167
干预措施: KL-A167 (Drug)
SKB264（Part3，HR+/HER2- BC）
Experimental
Participants received SKB264
干预措施: SKB264 (Drug)
结局指标
主要结局
Incidence and severity of adverse events (AEs)
时间窗: From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months
Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Objective Response Rate (ORR)
时间窗: From baseline to first documented objective response, up to 24 months
Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1.
次要结局
- Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of KL-A167(Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months)
- Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of KL-A167(Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months)
- Progression-free survival (PFS)(From baseline to the first documented disease progression or date of death (whichever occurs first), up to 24 months)
- Duration of response (DOR)(From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 24 months)
- Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of SKB264-ADC, SKB264-TAB and free KL610023(Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months)
- Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of SKB264-ADC, SKB264-TAB and free KL610023(Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months)
- Disease control rate (DCR)(From baseline to date of first documented objective response (CR, PR, and SD), up to 24 months)
- Anti-drug Antibodies (ADA) for SKB264 and KL-A167(Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: within 1 h before infusion of SKB264 (each cycle is 14 days), up to 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Non-small Cell Lung CancerNCT05816252Klus Pharma Inc.356
进行中（未招募）
2 期
SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsNCT05631262Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.321
进行中（未招募）
1 期
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Epithelial Ovarian CancerBreast CancerCervical CancerNon-Small Cell Lung CancerNCT04152499Klus Pharma Inc.1,410
招募中
3 期
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerTriple Negative Breast CancerNCT06279364Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.524
进行中（未招募）
3 期
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT06448312Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.406